Seth E Karol

List of Publications by Year
in descending order

71 papers	1,264 citations	471509 17 h-index	414414 32 g-index
71 all docs	71 docs citations	71 times ranked	2084 citing authors

#	Article	IF	Citations
1	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. Haematologica, 2022, 107, 371-380.	3.5	5
2	Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy. Frontiers in Oncology, 2022, 12, 845540.	2.8	10
3	Dasatinib does not exacerbate dexamethasoneâ€induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy. Pediatric Blood and Cancer, 2022, 69, e29490.	1.5	1
4	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Advances, 2022, 6, 5737-5749.	5.2	20
5	Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice. Haematologica, 2021, 106, 2095-2101.	3.5	6
6	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. Blood, 2021, 137, 1550-1552.	1.4	3
7	Ultrasound has limited diagnostic utility in children with acute lymphoblastic leukemia developing pancreatitis. Pediatric Blood and Cancer, 2021, 68, e28730.	1.5	7
8	Association ofGATA3Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2021, 113, 408-417.	6.3	16
9	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. Clinical Pharmacology and Therapeutics, 2021, 110, 794-802.	4.7	7
10	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Diseaseâ€“Directed Therapy. Blood Cancer Discovery, 2021, 2, 326-337.	5.0	71
11	Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase. Cancer Chemotherapy and Pharmacology, 2021, 88, 655-664.	2.3	5
12	Epidural blood patch for post-dural puncture headaches in adult and paediatric patients with malignancies: a review. British Journal of Anaesthesia, 2021, 126, 1200-1207.	3.4	5
13	Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models. Pediatric Blood and Cancer, 2021, 68, e29183.	1.5	6
14	Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Diabetes and Endocrinology,the, 2021, 9, 622-637.	11.4	29
15	Diabetes mellitus among adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort Study. Cancer, 2020, 126, 870-878.	4.1	17
16	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28040.	1.5	38
17	Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. Cancer Medicine, 2020, 9, 6550-6555.	2.8	7
18	Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment. Blood, 2020, 136, 2955-2958.	1.4	3

#	Article	IF	Citations
19	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer, 2020, 126, 4800-4805.	4.1	12
20	Team approach: Management of osteonecrosis in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28509.	1.5	6
21	Predicting success of desensitization after pegaspargase allergy. Blood, 2020, 135, 71-75.	1.4	20
22	Wholeâ€joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma. Pediatric Blood and Cancer, 2020, 67, e28336.	1.5	6
23	Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062072092757.	2.5	13
24	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncology, The, 2020, 21, 551-560.	10.7	92
25	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 329-344.	13.2	44
26	Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 189, e177-e181.	2.5	9
27	HLA Haplotype DRB1*07:01-DQA1*02:01-DQB1*02:02 Predicts Pegaspargase Hypersensitivity. Journal of Allergy and Clinical Immunology, 2020, 145, AB98.	2.9	0
28	Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase. Pediatric Blood and Cancer, 2020, 67, e28244.	1.5	5
29	Pharmacogenomics and ALL treatment: How to optimize therapy. Seminars in Hematology, 2020, 57, 130-136.	3.4	9
30	Long-Term Functional Outcomes Among Childhood Survivors of Cancer Who Have a History of Osteonecrosis. Physical Therapy, 2020, 100, 509-522.	2.4	13
31	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. Blood, 2020, 136, 39-40.	1.4	3
32	Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. Blood, 2020, 136, 23-24.	1.4	3
33	Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles. Blood, 2020, 136, 30-31.	1.4	4
34	Proposed Scheme for Dosing Venetoclax in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships. Blood, 2020, 136, 11-12.	1.4	0
35	Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. Blood, 2020, 136, 37-38.	1.4	8
36	A quality improvement project to improve pediatric medical provider sleep and communication during night shifts. International Journal for Quality in Health Care, 2019, 31, 633-638.	1.8	3

#	Article	IF	Citations
37	Hypertension is a modifiable risk factor for osteonecrosis in acute lymphoblastic leukemia. Blood, 2019, 134, 983-986.	1.4	12
38	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. Journal of Clinical Oncology, 2019, 37, 2051-2061.	1.6	61
39	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. PLoS ONE, 2019, 14, e0216328.	2.5	7
40	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatric Blood and Cancer, 2019, 66, e27681.	1.5	8
41	Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoidâ€induced osteonecrosis. Pediatric Blood and Cancer, 2019, 66, e27669.	1.5	11
42	Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study. Blood, 2019, 134, 2649-2649.	1.4	12
43	Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology, 2019, 37, 10004-10004.	1.6	3
44	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2019, 134, 178-178.	1.4	0
45	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. Blood, 2018, 132, 2697-2697.	1.4	2
46	Zoledronic Acid Reduces Osteonecrosis and Anti-Leukemic Efficacy in Murine Models of Acute Lymphoblastic Leukemia Therapy. Blood, 2018, 132, 4029-4029.	1.4	0
47	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. Blood, 2018, 132, 2665-2665.	1.4	0
48	Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. Leukemia, 2017, 31, 1325-1332.	7.2	25
49	Osteonecrosis is unrelated to hip anatomy in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2017, 64, e26407.	1.5	1
50	Genomeâ€Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. Clinical Pharmacology and Therapeutics, 2017, 102, 131-140.	4.7	50
51	Palmarâ€plantar erythrodysesthesia syndrome following treatment with highâ€dose methotrexate or highâ€dose cytarabine. Cancer, 2017, 123, 3602-3608.	4.1	11
52	Genetics of pleiotropic effects of dexamethasone. Pharmacogenetics and Genomics, 2017, 27, 294-302.	1.5	17
53	Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clinical Pharmacology and Therapeutics, 2017, 101, 373-381.	4.7	40
54	Comparison of genome sequencing and clinical genotyping for pharmacogenes. Clinical Pharmacology and Therapeutics, 2016, 100, 380-388.	4.7	46

#	Article	IF	Citations
55	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood, 2016, 127, 558-564.	1.4	56
56	Germline exome variation in children with acute lymphoblastic leukemia (ALL): Preliminary Findings. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S177.	0.4	0
57	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2015, 126, 1770-1776.	1.4	102
58	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood, 2015, 126, 69-75.	1.4	64
59	Effect of Premedications in a Murine Model of Asparaginase Hypersensitivity. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 541-551.	2.5	16
60	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nature Genetics, 2015, 47, 607-614.	21.4	126
61	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. British Journal of Haematology, 2015, 168, 94-101.	2.5	31
62	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. Blood, 2015, 126, 3714-3714.	1.4	2
63	Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. PLoS ONE, 2015, 10, e0135134.	2.5	13
64	Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia. Blood, 2015, 126, 250-250.	1.4	0
65	A Murine Model of Asparaginase Allergy. Blood, 2014, 124, 2295-2295.	1.4	0
66	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. Blood, 2014, 124, 63-63.	1.4	6
67	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 3722-3722.	1.4	0
68	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. Blood, 2013, 122, 490-490.	1.4	0
69	Linkage analysis of neointimal hyperplasia and vascular wall transformation after balloon angioplasty. Physiological Genomics, 2006, 25, 286-293.	2.3	10
70	Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. Blood, 2006, 108, 2463-2469.	1.4	26
71	Vaccines against <scp>SARSâ€CoV</scp> â€2 are safe to administer in patients with antibodies to pegaspargase. Cancer Medicine, 0, , .	2.8	0